Classical and novel retinoids: Their targets in cancer therapy

Leukemia

Volumn 16, Issue 4, 2002, Pages 463-472

  Fontana, J A ^a   Rishi, A K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

4 HPR; 6 3 (1 adamantyl) 4 hydroxyphenyl 2 naphthalene carboxylic acid; AHPN; CD437; N(4 hydroxyphenyl) retinamide; Retinoids

Indexed keywords

4 [1 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CYCLOPROPYL]BENZOIC ACID; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; CELL NUCLEUS RECEPTOR; FENRETINIDE; HISTONE DEACETYLASE INHIBITOR; PLACEBO; PROTEIN P21; RETINOIC ACID RECEPTOR; RETINOID; RETINOID X RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BREAST CARCINOMA; BREAST SURGERY; CANCER CELL; CANCER THERAPY; CELL DIFFERENTIATION; CELL GROWTH; CELL TYPE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRECANCER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECEPTOR BINDING; RECEPTOR UPREGULATION; REVIEW; SCID MOUSE; SIDE EFFECT;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; FENRETINIDE; HUMANS; NEOPLASMS; RECEPTORS, RETINOIC ACID; RETINOIDS;

EID: 0036234606     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402414     Document Type: Review

References (121)

1. Retinoid mechanisms and cyclins
2. The retinoids and cancer prevention mechanism
3. Retinoids in chemoprevention and differentiation therapy
4. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer
5. Retinoids and human cancer
6. Retinoids and interferon-α in the prevention and treatment of preneoplastic and neoplastic diseases. A review
7. The retinoid receptors
8. Retinoids, retinoid responsive genes, cell differentiation and cancer
9. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor
10. 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα
11. Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast
12. Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by proteases mapping
13. The N-terminal portion of domain E of retinoic acid receptors α and β is essential for the recognition of retinoic acid and various analogs
14. Promoter content and responsive element-dependent specificity of the transcriptional activation and modulating function of the retinoic acid receptor
15. Targeted disruption of retinoic acid receptor α (RARα) and RARγ results in receptor specific alternations in retinoic acid mediated differentiation and retinoic acid metabolism
16. Loss of retinoic acid receptor γ function in F9 cells by gene disruption in aberrant Hux 1 expression and differentiation upon retinoic acid treatment
17. Synthetic retinoids and their usefulness in biology and medicine
18. Nuclear receptor that identifies a novel retinoic acid response pathway
19. Retinobenzoic acids 1 structure-activity relationships of aromatic amides with retinoidal activity
20. Synergistic activation of retinoic acid (RA)-responsive genes and induction of embryonal carcinoma cell differentiation by an RA receptor α (RARα)-, RARβ- or RARγ- selective ligand in combination with a retinoid X receptor specific lig
21. Antagonism between retinoic acid receptors
22. Retinoid X receptor-specific retinoids inhibit the ability of retinoic acid receptor specific retinoids to increase the level of insulin-like growth factor binding protein-3 in human ectocervical epithelial cells
23. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
24. Role of CBP/300 in nuclear receptor signalling
25. Structure-activity relationships of retinoids in hamster tracheal organ culture
26. 6′-Substituted naphthalene-2-carboxylic acid analogs, a new class of retinoic acid subtype-specific ligands
27. Identification of synthetic retinoids with selectivity for human nuclear retinoic receptor γ
28. Structural modifications of 6-naphthalene-2-carboxylate retinoids
29. Retinoid selective for retinoid X receptor response pathways
30. Conformational effects on retinoid receptor selectivity 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity
31. Synthesis and structure activity relationships of novel retinoid X receptor-selective retinoids
32. Use of all-trans retinoic acid in the treatment of acute leukemias
33. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all trans retinoic acid)
34. A clinical and experimental study on all trans retinoic acid-treated acute promyelocytic leukemia patients
35. All trans retinoic acid for promyelocytic leukemia-results of the New York study
36. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia
37. The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR
38. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML
39. Retinoic acid induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated through the retinoic acid receptor (RARα)
40. Over expression of retinoic acid receptor α suppresses myeloid cell differentiation at the promyelocyte stage
41. A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage
42. Function of RAR alpha during maturation of neutrophils
43. Transcriptional regulation in acute promyelocytic leukemia
44. Positive and negative regulation of granulopoiesis by endogenous RAR alpha
45. Deconstructing a disease: RARα, its fusion partners and their roles in the pathogenesis of acute promyelocytic leukemia
46. The molecular biology of acute promyelocytic leukemia
47. The PML-RARα gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells
48. Transgenic expression of PML/RARα impairs myelopoiesis
49. Structure, localization and transcriptional properties of two classes of retinoic acid receptor α fusion proteins in acute promyelocytic leukemia (APL): Structural similarities with a new family of oncoproteins
50. The PML-retinoic acid receptor α translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1
51. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein
52. Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells
53. STAT 1 is induced and activated by all-trans retinoic acid and in acute promyelocytic leukemia cells
54. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia though formation of homodimers
55. Oligomerization of RAR and AML 1 transcription factors as anovel mecahism of oncogene activation
56. Distinct leukemia prototypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RAR alpha and NPM-RAR alpha
57. Histone deacetylase-targeted treatment restores retinoic acid signalling and differentiation in acute leukemia
58. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia
59. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis
60. All trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia patients
61. All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
62. Clinical pharmacology of oral all trans retinoic acid with acute promyelocytic leukemia
63. Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans-retinoic acid by human microsomes generically enriched in specified cytochrome p450 isoforms
64. Constitutive expression of cellular retinoic acid binding protein II and lack of correlation with sensitivity to all trans retinoic acid in acute promyelocytic leukemia cells
65. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: A study of in vitro sensitivity and cellular retinoic acid binding protein levels in leukemia cells
66. Introduction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients
67. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
68. Resistance to all trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells
69. Pulsed ATRA as a single therapy restores long term remission in PML-RAR alpha positive acute promyelocytic leukemia patients: Real time quantification of minimal residual disease. A pilot study
70. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy
71. N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant cell lines including those unresponsive to retinoic acid
72. The occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB306 is associated with altered expression of pml/RAR protein
73. N-(4-hydroxyphenyl) retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma
74. 4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors
75. Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senesing normal mammary epithelial cells
76. Retinoic acid beta expression and growth inhibition of gynecological cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide
77. Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: A possible mechanism of action via regulation of retinoid receptors expression
78. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression
79. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl) retinamide in F9 embryonal carcinoma cells
80. Induction of apoptosis by N-(4-hydroxyphenyl) retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors and apoptosis related genes in human prostate carcinoma cells
81. Mediation of N-(4-hydroxyphenyl) retinamide-induced apoptosis in human cancer cells by different mechanisms
82. Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma
83. Involvement of reactive oxygen species in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells
84. Role of antioxidants and intracellular free radicals in retinamide-induced cell death
85. Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase 3 in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells
86. Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl) retinamide-treated mammary tumors
87. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2
88. pRb and Cdk regulation by N-(4-hydroxyphenyl) retinamide
89. Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation and changes in p34 cdc 2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemia cells
90. Safety of the synthetic retinoid fenretinide: Long-term results from a controlled clinical trial for the prevention of contralateral breast cancer
91. Fenretinide and cancer prevention
92. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results
93. Effects of receptor class and subtype: Selective retinoids and an apoptosis inducing retinoid on the adherent growth of the NIH: OVCAR-3 ovarian cancer cell line in culture
94. P53 independent G1/G0 arrest and apoptosis induced by a novel retinoid in human breast cancer cells
95. Retinoic acid resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity
96. Induction of apoptosis in human non-small cell lung carcinoma cells by the novel synthetic retinoid CD437
97. Differential responses of normal, premalignant and malignant bronchial epithelial cells to receptor selective retinoids
98. Dual mechanisms of action of the retinoid CD437: Nuclear retinoic acid receptor-mediated suppression of squamous differentiation and receptor-independent apoptosis in UMSCC2B human head and neck squamous cell carcinoma cells
99. Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors
100. Activation of the p38 and JNK/SAPK mitogen-activated protein kinase pathways during apoptosis is mediated by a novel retinoid
101. Posttranscriptional regulation of p21 WAF1/CIP1 expression in human breast carcinoma cells
102. Synthetic retinoid CD437 induces S-phase arrest and apoptosis in human prostate cancer cells LNCaP and PC-3
103. S-phase arrest and apoptosis in normal mammary epithelial cells by a novel retinoid
104. Cyclin A-kinase regulation of E2F-1 DNA binding function underlines suppression of an S phase checkpoint
105. Deficiency of retinoblastoma protein leads to inappropriate S phase entry, activation of E2F-responsive genes and apoptosis
106. E2F-1 induced apoptosis requires DNA binding but not transactivation and is inhibited by retinoblastoma protein through direct interaction
107. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells
108. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid G-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of trail receptors
109. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells
110. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells
111. Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines
112. The novel retinoid 6-[3-(1 adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus
113. Evidence of lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia cells
114. Retinoid induced apoptosis through a retinoic acid nuclear receptor independent pathway
115. Identification of a unique binding protein specific for a novel retinoid inducing cellular apoptosis
116. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro and causes growth inhibition in xenografts in vivo
117. Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo
118. Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo
119. Apoptosis induction and potent antrestrogen receptor-negative activity in vivo by a retinoid antagonist
120. Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid
121. Apoptosis induction in cancer cells by a novel analog of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid lacking retinoid transcriptional activity